We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Newly Identified Biomarker Indicates Risk of Breast Cancer Bone Metastasis

By LabMedica International staff writers
Posted on 28 Sep 2015
Print article
Image: Top, breast cancer tumor cells negative for the bone metastasis marker, MFA. Bottom, breast cancer tumor cells positive for the marker (Photo courtesy of Gomis Laboratory, Institute for Research in Biomedicine, Barcelona).
Image: Top, breast cancer tumor cells negative for the bone metastasis marker, MFA. Bottom, breast cancer tumor cells positive for the marker (Photo courtesy of Gomis Laboratory, Institute for Research in Biomedicine, Barcelona).
Cancer researchers have identified a gene that is critically linked to the ability of some breast cancer tumors to metastasize to the bone and which may be developed into a biomarker to identify patients at risk for this development.

There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis, which occurs in about 15%–20% of patients with estrogen-receptor-positive breast tumors. These tumors tend to metastasize to the bone, and represent 80% of all breast cancers.

Investigators at the Institute for Research in Biomedicine (Barcelona, Spain) analyzed more than 900 clinical samples of primary breast tumors while looking for genetic variations that favored bone metastasis.

They reported in the September 15, 2015, online edition of the Journal of the National Cancer Institute that patients with tumors in which the MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog) gene was altered had a risk of metastasis to the bone that was 14 times higher than in those patients in which the gene was unaltered.

"This gene reliably predicts metastasis to the bone. Studying whether it is highly expressed in breast cancer patients to determine whether this also happens in a clinical setting is an important next step. It could improve the quality of life of these patients and the way clinicians manage their cancer. And this is exactly what we are doing," said senior author Dr. Roger Gomis, oncology group leader at the Institute for Research in Biomedicine.

The findings obtained in this study have led to the creation of the company Inbiomotion (Barcelona, Spain), which has developed the tools necessary to begin clinical trials. An initial clinical trial will validate the use of the marker in some 3,300 patients.

Related Links:

Institute for Research in Biomedicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article


Molecular Diagnostics

view channel
Image: A simple method can predict risk of worsening of widespread kidney disease (Photo courtesy of 123RF)

Simple Measurement Predicts Risk of Rapid Progression of Chronic Kidney Disease

Chronic kidney disease (CKD) is increasingly becoming a major health issue worldwide. For those diagnosed with CKD, the rate of disease progression can vary, with some individuals experiencing a rapid... Read more


view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more


view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more


view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.